Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
26.96
+0.56 (2.12%)
Nov 21, 2024, 1:13 PM EST - Market open

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.

Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.

It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc.
Celldex Therapeutics logo
Country United States
Founded 1983
IPO Date Mar 10, 2008
Industry Biotechnology
Sector Healthcare
Employees 160
CEO Anthony Marucci

Contact Details

Address:
Perryville III Building, Suite 220
Hampton, New Jersey 08827
United States
Phone 908 200 7500
Website celldex.com

Stock Details

Ticker Symbol CLDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000744218
CUSIP Number 15117B202
ISIN Number US15117B2025
Employer ID 13-3191702
SIC Code 2835

Key Executives

Name Position
Anthony S. Marucci M.B.A. Founder, President, Chief Executive Officer and Director
Dr. Tibor Keler Ph.D. Founder, Chief Scientific Officer and Executive Vice President
Dr. Margo Heath-Chiozzi M.D. Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D. Senior Vice President and Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D. Co-Founder and Member of Scientific Advisory Board
Sarah Cavanaugh Senior Vice President of Corporate Affairs and Administration
Freddy A. Jimenez Esq. Senior Vice President and General Counsel
Dr. Ronald A. Pepin Chief Business Officer and Senior Vice President
Elizabeth Crowley Chief Product Development Officer and Senior Vice President
Dr. Richard M. Wright Ph.D. Chief Commercial Officer and Senior Vice President

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report